- Home
- GGAL vs HALO Comparison
GGAL vs HALO Comparison
Compare GGAL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | HALO |
|---|---|---|
| Founded | 1905 | 1998 |
| Country | Argentina | United States |
| Employees | 10079 | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.8B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | GGAL | HALO |
|---|---|---|
| Price | $40.99 | $67.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $69.00 | ★ $78.64 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 03-07-2023 | 05-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $62.29 | $28.24 |
| Revenue Next Year | $22.88 | $12.56 |
| P/E Ratio | ★ $13.36 | $56.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $51.06 |
| 52 Week High | $65.48 | $82.22 |
Technical Indicators
Market Signals| Indicator | GGAL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 52.10 |
| Support Level | $39.97 | $62.53 |
| Resistance Level | $45.01 | $70.93 |
| Average True Range (ATR) | 1.87 | 2.67 |
| MACD | -0.07 | 0.43 |
| Stochastic Oscillator | 28.25 | 42.57 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.